Literature DB >> 11371023

Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor.

A Mihaila1, G M Tremblay.   

Abstract

Elafin and secretory leukocyte protease inhibitor (SLPI) are two structurally related serine protease inhibitors present in the lung. The cellular origin of elafin in the alveolar space is unknown. It has been suggested that at least one alveolar leukocyte population express elafin. We therefore postulated that the alveolar macrophage, as the most numerous leukocyte in the alveolar space, express elafin. On the other hand, it is unclear whether human alveolar macrophages are a source of SLPI. In the present study, we showed by RT-PCR that human alveolar macrophages, but not peripheral blood monocytes, express elafin and SLPI transcripts. Elafin, but not SLPI, mRNA expression was increased time dependently in alveolar macrophages stimulated with Saccharopolyspora rectivirgula antigen (50 microg/ml), a causative agent of hypersensitivity pneumonitis, but not LPS (10 microg/ml). Intracellular or cell-associated elafin protein accumulated after 24 h of culture only in S. rectivirgula antigen-stimulated alveolar macrophages as shown by Western blot. In contrast, alveolar macrophages release 50+/-6 pg/ml of SLPI in culture medium with no increase in function of time. Alveolar macrophages could be a source of elafin in the lung. In addition to lung structural cells, SLPI could also be derived from alveolar macrophages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371023     DOI: 10.1515/znc-2001-3-420

Source DB:  PubMed          Journal:  Z Naturforsch C J Biosci        ISSN: 0341-0382


  13 in total

1.  Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Sumiti Jain; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

3.  Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid.

Authors:  O Laugisch; M Schacht; A Guentsch; T Kantyka; A Sroka; H R Stennicke; W Pfister; A Sculean; J Potempa; S Eick
Journal:  Mol Oral Microbiol       Date:  2011-12-07       Impact factor: 3.563

Review 4.  Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants.

Authors:  Megan Meyer; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

5.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

6.  Human pre-elafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media.

Authors:  Audrey Bellemare; Nathalie Vernoux; Dany Morisset; Yves Bourbonnais
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

Review 7.  Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

8.  Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.

Authors:  Nicolas Guyot; Marcus W Butler; Paul McNally; Sinead Weldon; Catherine M Greene; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

9.  Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells.

Authors:  Catherine M Greene; Noel G McElvaney; Shane J O'Neill; Clifford C Taggart
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment.

Authors:  Thomas S Wilkinson; Kevin Dhaliwal; Thomas W Hamilton; Alexander F Lipka; Lesley Farrell; Donald J Davidson; Rodger Duffin; Andrew Conway Morris; Chris Haslett; John R W Govan; Christopher D Gregory; Jean-Michel Sallenave; A John Simpson
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.